[6] [6] Kar S, Doshi SK, Sadhu A, et al. Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial[J]. Circulation, 2021, 143(18):1754-1762.

[7] [7] Alkhouli M, Freeman JV, Ellis CR, et al. First experience with amulet in the United States: early insights from EMERGE LAA postapproval study[J]. JACC Cardiovasc Interv, 2024, 17(3):422-434.

[8] [8] Lakkireddy D, Thaler D, Ellis CR, et al. Amplatzer amulet left atrial appendage occluder versus watchman device for stroke prophylaxis (Amulet IDE): a randomized, controlled trial[J]. Circulation, 2021, 144(19):1543-1552.

[9] [9] Galea R, Meneveau N, De Marco F, et al. One-year outcomes after amulet or watchman device for percutaneous left atrial appendage closure: a prespecified analysis of the SWISS-APERO randomized clinical trial[J]. Circulation, 2024, 149(6):484-486.

[10] [10] Freeman JV, Higgins AY, Wang Y, et al. Antithrombotic therapy after left atrial appendage occlusion in patients with atrial fibrillation[J]. J Am Coll Cardiol, 2022, 79(18):1785-1798.

[11] [11] Su F, Gao C, Liu J, et al. Periprocedural outcomes associated with use of a left atrial appendage occlusion device in China[J]. JAMA Netw Open, 2022, 5(5):e2214594.

[12] [12] Della Rocca DG, Magnocavallo M, Di Biase L, et al. Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion[J]. JACC Cardiovasc Interv, 2021, 14(21):2353-2364.

[13] [13] Afzal MR, Gabriels JK, Jackson GG, et al. Temporal changes and clinical implications of delayed peridevice leak following left atrial appendage closure[J]. JACC Clin Electrophysiol, 2022, 8(1):15-25.

[14] [14] Alkhouli M, De Backer O, Ellis CR, et al. Peridevice leak after left atrial appendage occlusion: incidence, mechanisms, clinical impact, and management[J]. JACC Cardiovasc Interv, 2023, 16(6):627-642.